Pfizer
New York, NYfiles as Pfizer Inc
$170m in 17 US stocks at the end of 30 June 2026. The top 10 are 95.8% of the money. It changed about 28.3% of the portfolio this quarter.
Value
$170m
Stocks
17
Top 10 share
95.8%
Turnover
28.3%
What changed this quarter
New
Bought for the first time this quarter.
None this quarter.
Added
Bought more of a stock they already held.
None this quarter.
Cut
Sold some of their stake.
- Oric PharmaceuticalsORIC2.1% of the fund-92%
- Zura BioZURA1.7% of the fund-81%
- NextCureNXTC<0.1% of the fund-71%
Sold out
Sold their entire stake.
- Q32 BioQTTB-100%
Holdings
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| Allogene TherapeuticsALLO | 27.5% | $47m | 22,032,040 | Held |
| CelcuityCELC | 17.3% | $30m | 295,652 | Held |
| ArvinasARVN | 16.2% | $28m | 3,457,815 | Held |
| Pyxis OncologyPYXS | 11.4% | $19m | 7,032,770 | Held |
| Wave Life SciencesWVE | 6.4% | $11m | 1,875,000 | Held |
| BiohavenBHVN | 4.7% | $8m | 505,645 | Held |
| Caribou BiosciencesCRBU | 4.6% | $8m | 4,690,431 | Held |
| Spero TherapeuticsSPRO | 3.1% | $5m | 2,362,348 | Held |
| Zentalis PharmaceuticalsZNTL | 2.3% | $4m | 953,834 | Held |
| Oric PharmaceuticalsORIC | 2.1% | $4m | 372,904 | -92% |
| Cardiff OncologyCRDF | 1.8% | $3m | 2,411,575 | Held |
| Zura BioZURA | 1.7% | $3m | 538,841 | -81% |
| AgomAb Therapeutics NVAGMB | 0.6% | $1m | 75,000 | Held |
| Bolt BiotherapeuticsBOLT | <0.1% | $133,832 | 31,305 | Held |
| NextCureNXTC | <0.1% | $72,967 | 44,347 | -71% |
| Ginkgo Bioworks HoldingsDNA | <0.1% | $30,012 | 2,928 | Held |
| Senseonics HoldingsSENS | <0.1% | $12,418 | 2,171 | Held |
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is down 70.4% since 30 June 2025.
Where the money is
Health care100.0%
Industrials0.0%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.